April 24, 2018 by Dale Yuzuki
At the recent American Association for Cancer Research (#AACR18), a Pillar Biosciences affiliate Shanghai Zhengu Biotech Limited’s lead scientist Jian Feng Xiao, Ph.D. presented a poster entitled “Evaluation of ONCOReveal Lung [more]
April 11, 2018 by Dale Yuzuki
At the recent Association for Molecular Pathology conference in Salt Lake City, Utah, we had the opportunity to ask Dr. Gang Song, Chief Executive Officer of Pillar Biosciences to talk [more]
March 27, 2018 by Dale Yuzuki
The complexity of the NGS process, compounded by sample processing, results in unique challenges for the clinical oncology laboratory Analysis of clinical samples for matching patients to targeted therapy is [more]
March 9, 2018 by Dale Yuzuki
The clinical oncology laboratory faces a challenge in implementing new technology, and with the advent of next-generation sequencing, that level of complexity has expanded on both the wet-laboratory side as well as the data-processing side.
February 26, 2018 by Dale Yuzuki
You are a clinical laboratory director responsible for the operations of a modern molecular pathology laboratory. This includes using next-generation sequencing as a laboratory-developed test to characterize individual patient samples to tailor individual treatment. Your work and profession have immediate impact on improving health, and you have adjusted to the increasingly rapid changes in molecular diagnostics.